FDA Pharmacogenomics Guide Needs Process To Accept Biomarkers – PhRMA

FDA should define a process to prospectively validate biomarkers for pharmacogenomic product approval, the Pharmaceutical Research & Manufacturers of America said in comments on an FDA draft guidance